All In Biotech

Drug Trial Radar · NCT03102723

Platelet Inhibition to Target Reperfusion Injury

Platelet Inhibition to Target Reperfusion Injury: The PITRI Trial

Last checked: Nov 20, 2026Latest source record: Apr 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

228

Actual

Start

Oct 1, 2017

Primary completion

Dec 2022

Study completion Dec 2022

Sponsor

Lead sponsor
National Heart Centre SingaporeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tan Tock Seng Hospital; National University Hospital, Singapore; Khoo Teck Puat Hospital; Changi General Hospital; Sengkang General Hospital
First posted
Apr 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There remains a clinical need to improve health outcomes in patients with ischemic heart disease (IHD) the leading cause of death and disability in Singapore and worldwide. One neglected therapeutic target is 'myocardial reperfusion injury' in ST-segment elevation myocardial infarction (STEMI) patients treated by primary percutaneous coronary intervention (PPCI). This results in microvascular obstruction (MVO) and cardiomyocyte death and contributes upto 50% of the final myocardial infarct (MI) size. Cangrelor, a potent intravenous platelet P2Y12 inhibitor with rapid onset and offset of action, has been demonstrated in experimental animal studies to reduce MI size when administered prior to reperfusion. Whether Cangrelor given together with Ticagrelor would be more effective at reducing MI size in STEMI patients treated by PPCI is not known and is investigated in the Platelet Inhibition to Target Reperfusion Injury (PITRI) trial.

Conditions

  • STEMI

Interventions

  • CangrelorDrug

    1. Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials. Or 2. Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Myocardial infarct size by CMR at Day 2 to 7Time frame: 2-7 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • National University Hospital (NUH)

    Singapore, Singapore

  • Tan Tock Seng Hospital (TTSH)

    Singapore, Singapore

  • Khoo Teck Puat Hospital

    Singapore, Singapore

  • Changi General Hospital

    Singapore, Singapore

  • SengKang General Hospital

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.